Akebia Therapeutics, Inc. SEC filings AKBA
Akebia Therapeutics, Inc. has 886 filings in SEC EDGAR's recent list, going back to Apr 8, 2011. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 5, 2026 | — |
| S-8 | Employee stock plan registration | Aug 7, 2025 | — |
| 424B5 | Prospectus supplement | Mar 20, 2025 | — |
| 424B5 | Prospectus supplement | Mar 19, 2025 | — |
| S-8 | Employee stock plan registration | Jan 30, 2025 | — |
| S-3 | Shelf registration | Sep 3, 2024 | — |
| S-8 | Employee stock plan registration | Jan 30, 2024 | — |
| S-8 | Employee stock plan registration | Jun 6, 2023 | — |
| S-8 | Employee stock plan registration | Jan 30, 2023 | — |
| 424B5 | Prospectus supplement | Apr 7, 2022 | — |
| 424B5 | Prospectus supplement | Apr 7, 2022 | — |
| POS AM | Filing | Mar 1, 2022 | — |
| S-8 | Employee stock plan registration | Jan 28, 2022 | — |
| S-3ASR | Automatic shelf registration | Feb 25, 2021 | — |
| S-8 | Employee stock plan registration | Jan 22, 2021 | — |
| 424B5 | Prospectus supplement | May 12, 2020 | — |
| 424B5 | Prospectus supplement | May 11, 2020 | — |
| 424B5 | Prospectus supplement | Mar 12, 2020 | — |
| S-8 | Employee stock plan registration | Jan 24, 2020 | — |
| 424B5 | Prospectus supplement | Nov 12, 2019 | — |
| S-8 | Employee stock plan registration | Aug 8, 2019 | — |
| S-8 | Employee stock plan registration | Jan 25, 2019 | — |
| S-8 | Employee stock plan registration | Dec 13, 2018 | — |
| 424B3 | Prospectus | Oct 30, 2018 | — |
| S-4/A | Filing | Oct 29, 2018 | — |
| S-4/A | Filing | Oct 25, 2018 | — |
| S-4 | Registration for a merger or exchange | Oct 1, 2018 | — |
| 424B5 | Prospectus supplement | Mar 26, 2018 | — |
| 424B5 | Prospectus supplement | Mar 22, 2018 | — |
| S-3ASR | Automatic shelf registration | Mar 12, 2018 | — |
| S-8 | Employee stock plan registration | Jan 26, 2018 | — |
| 424B5 | Prospectus supplement | Jun 29, 2017 | — |
| 424B5 | Prospectus supplement | Jun 28, 2017 | — |
| S-8 | Employee stock plan registration | Mar 6, 2017 | — |
| S-3 | Shelf registration | May 5, 2016 | — |
| S-8 | Employee stock plan registration | Feb 10, 2016 | — |
| 424B5 | Prospectus supplement | Jan 8, 2016 | — |
| FWP | Free writing prospectus | Jan 7, 2016 | — |
| 424B5 | Prospectus supplement | Jan 4, 2016 | — |
| 424B5 | Prospectus supplement | Aug 11, 2015 | — |
| 424B5 | Prospectus supplement | Apr 17, 2015 | — |
| 424B5 | Prospectus supplement | Apr 14, 2015 | — |
| S-3/A | Form s-3/a (amendment no. 1) | Apr 13, 2015 | — |
| S-3 | Shelf registration | Apr 2, 2015 | — |
| S-8 | Employee stock plan registration | Jun 13, 2014 | — |
| 424B4 | Prospectus | Mar 21, 2014 | — |
| S-1MEF | Filing | Mar 19, 2014 | — |
| S-1/A | Amended registration statement | Mar 17, 2014 | — |
| FWP | Free writing prospectus | Mar 17, 2014 | — |
| S-1/A | Amended registration statement | Mar 7, 2014 | — |
| S-1/A | Amended registration statement | Mar 7, 2014 | — |
| S-1/A | Amended registration statement | Mar 4, 2014 | — |
| S-1 | Registration statement | Feb 14, 2014 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKBA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1517022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.